Pawan Kumar Raghav, PhD

Title(s)Postdoctoral Scholar, Surgery
SchoolSchool of Medicine
Address3333 California Street, #820
San Francisco CA 94118
Phone415-476-0795
ORCID ORCID Icon0000-0002-2440-7134 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Delhi, Delhi, IndiaB.Sc.2006Zoology, Chemistry, Botany
    Punjabi University Patiala, Patiala, IndiaM.Sc.2008Bioinformatics
    Jamia Hamdard, Delhi, IndiaP.G. Diploma2009Chemoinformatics
    The Global Open University, Nagaland, IndiaM.Phil2010Bioinformatics
    Bharathiar University, Coimbatore, IndiaPh.D2016Life Science
    INMAS, DRDO, Delhi, IndiaRA2017Stem Cells
    IIIT, Delhi, IndiaPostDoc2019Cancer Stem Cells
    AIIMS, Delhi, IndiaScientist D2020Stem Cells
    Collapse Awards and Honors
    INMAS DRDO2011  - 2016DRDO Research Fellowship
    SERB, DST2017  - 2019National Post-Doctoral Fellowship (N-PDF)
    ICMR2019  - 2019Travel Award
    Elsevier2019  - 2019Reviewer Biochimie, ISSN: 0300-9084
    ScienceFather2020  - 2020Best Research Award
    Institute of Scholars (InSc)2020  - 2020Research Excellence Award
    AJRRG2020  - 2020Reviewer, Asian Journal of Research and Reports in Gastroenterology
    InSc2020  - 2020Reviewer, International Journal of Basic and Applied Sciences, ISSN: 2227-5053
    Elsevier2021  - 2021Reviewer, Human Immunology, ISSN: 0198-88590l
    SAGE2021  - 2021Reviewer, SAGE Open Medical Case Reports, ISSN: 2050-313X
    Springer2021  - 2021Reviewer, Pharmacological Reports, ISSN: 1734-1140

    Collapse Overview 
    Collapse Overview
    Dr. Pawan Kumar Raghav completed his MSc in Bioinformatics (2008) from Punjabi University, Patiala, India; PG Diploma in Chemoinformatics (2009) from Jamia Hamdard; MPhil in Bioinformatics (2010) from The Global Open University, Nagaland; and Ph.D. at the Institute of Nuclear Medicine and Allied Sciences (INMAS), DRDO, Delhi in Life Sciences from Bharathiar University, Coimbatore. During his Ph.D., he designed molecules and evaluated their applications through response modification that regulates stem cells proliferation, differentiation, and apoptosis. His main research interest is in the field of drug designing against Cancer Stem Cells (CSCs). He has completed the Department of Science and Technology (DST), Government of India’s project as leading Principal Investigator (PI) in Department of Computational Biology, IIIT Delhi, India during his Post-Doc (2017-2019), awarded by DST, SERB. During this tenure, his research work included developing tools and databases using machine learning, deep learning algorithms, and new scoring function parameterizations for use in docking, simulations, and complex network analysis. Also, Dr. Pawan Kumar Raghav has worked as Scientist ‘D’ in Stem Cell Facility, AIIMS, New Delhi-110029, India. As a scientist, he carried out stem cell informatics, current Good Manufacturing Practices (cGMP), and tissue engineering experimental studies. Currently, he is working as a research scientist in Immunogenetics and Transplantation Lab, Department of Surgery, University of California San Francisco (UCSF), San Francisco, California. In UCSF, he is developing novel approaches for investigating immune/inflammatory mechanisms of allograft injury and discovering new biomarkers and therapeutics in solid organ and bone marrow transplantation. He is the recipient of several awards and honors, including the ICMR Travel Award to deliver an oral talk in 11th world congress & expo on cell & stem cell research ORLANDO, the USA in 2019, Research Excellence Award from Institute of Scholars (InSc), and best Research Award in 2020 from Science Father. He has published more than 40 publications, including international research articles, book chapters, books, and Indian intellectual property rights for 03 patents. His research activities and broad experience shows his significant contribution to stem cells engineering, nanotechnology, and computational biology.

    Collapse Research 
    Collapse Research Activities and Funding
    Role of Bcl-2 in Cancer Stem Cells and apoptosis pathway elucidation for development of novel molecules
    DST SERB Apr 19, 2019
    Role: Main PI
    Description: The molecules developed through this project will be used to eradicates leukemic stem cells. This study will identify molecules which we believe, will definitely contribute to the development of future therapeutic drugs. In silico approach will reveal identified molecules function in HSCs signalling. The identified molecules through QSAR and systems biology approach will also proceed for synthesis of lead molecules to evaluate their efficacy and adverse effects. This work will lead us one step ahead towards anti-CSCs and anti-LSCs drug discovery. The new molecules will serve as new drug-like candidate against the targets using drug discovery approach. The optimized QSAR model will be made online using various machine learning techniques.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. Journal of Pharmacological Sciences. 2023; 152(1):1-21. Pawan Kumar Raghav, Zoya Mann, Simran Kaur Ahluwalia, Raja Rajalingam. View Publication.
    2. Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. J Pharmacol Sci. 2023 May; 152(1):1-21. Raghav PK, Mann Z, Ahluwalia SK, Rajalingam R. PMID: 37059487; PMCID: PMC9930377.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    3. Experimental and clinical data analysis for identification of COVID-19 resistant ACE2 mutations. Scientific Reports, Springer Nature. 2023; 13(2351):1-43. Pawan Kumar Raghav, Aditya Raghav, Anjali Lathwal, Archit Saxena, Zoya Mann, Manisha Sengar & Raja Rajalingam. View Publication.
    4. Hematopoietic Stem Cell Factors: Their Functional Role in Self-Renewal and Clinical Aspects. Front Cell Dev Biol. 2022; 10:664261. Mann Z, Sengar M, Verma YK, Rajalingam R, Raghav PK. PMID: 35399522; PMCID: PMC8987924.
      View in: PubMed   Mentions: 13  
    5. Therapeutic Potential of Chemical Compounds in Targeting Cancer Stem Cells. Handbook of Oxidative Stress and Cancer: Therapeutic Aspect. 2022; 1:1-39. Pawan Kumar Raghav, Zoya Mann, Sujata Mohanty. View Publication.
    6. Mesenchymal stem cell-based nanoparticles and scaffolds in regenerative medicine. Eur J Pharmacol. 2022 Mar 05; 918:174657. Raghav PK, Mann Z, Ahlawat S, Mohanty S. PMID: 34871557.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    7. Therapeutic effect of natural compounds in targeting ROS induced cancer. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects. 2021; 47. Pawan Kumar Raghav, Zoya Mann, Vishnu Krishnakumar, Sujata Mohanty. View Publication.
    8. Graphene nanofiber composites for enhanced neuronal differentiation of human mesenchymal stem cells. Nanomedicine (Lond). 2021 09; 16(22):1963-1982. Rawat S, Jain KG, Gupta D, Raghav PK, Chaudhuri R, Shakeel A, Arora V, Sharma H, Debnath D, Kalluri A, Agrawal AK, Jassal M, Dinda AK, Patra P, Mohanty S. PMID: 34431318.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    9. Nanomedicine. Graphene nanofiber composites for enhanced neuronal differentiation of human mesenchymal stem cells. 2021. Sonali Rawat, Krishan Gopal Jain, Deepika Gupta, Pawan Kumar Raghav, Rituparna Chaudhuri, Pinky, Adeeba Shakeel, Varun Arora, Harshita Sharma, Debika Debnath, Ankarao Kalluri, Ashwini K. Agrawal, Manjeet Jassal, Amit K. Dinda, Prabir Patra, Sujata Mohanty . View Publication.
    10. CoVAM: Complementary and Alternative Medicine Clinical Trials Database for COVID-19 Disease. Journal of Antivirals & Antiretrovirals. 2021; 13(228):1-4. Vishwas Sharma, Zoya Mann, Amitesh Sharma, Avani Srivastava, Pawan Kumar Raghav, Ritu Singh, Amrita Nandan. View Publication.
    11. Handbook of Oxidative Stress in Cancer: Mechanistic Aspects (Sajal Chakraborti, Bimal K Ray, Sushanta Roychowdhury). Systems Biology Resources and Their Applications to Understand the Cancer. 2021; 1-35. Pawan Kumar Raghav, Zoya Mann, Pranav K. Pandey, and Sujata Mohanty. View Publication.
    12. PU.1 Mimic Synthetic Peptides Selectively Bind with GATA-1 and Allow c-Jun PU.1 Binding to Enhance Myelopoiesis. Int J Nanomedicine. 2021; 16:3833-3859. Raghav PK, Gangenahalli G. PMID: 34113102; PMCID: PMC8187006.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    13. Human cell receptors: potential drug targets to combat COVID-19. Amino Acids. 2021 Jun; 53(6):813-842. Raghav PK, Kalyanaraman K, Kumar D. PMID: 33950300; PMCID: PMC8097256.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    14. Cancer stem cells targets and combined therapies to prevent cancer recurrence. Life Sci. 2021 Jul 15; 277:119465. Raghav PK, Mann Z. PMID: 33831426.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    15. Synthetic peptide, nanoparticle formulation and implementation thereof. 2020. Gurudutta Gangenahalli, Raghav Pawan Kumar. .
    16. Are graphene and graphene-derived products capable of preventing COVID-19 infection? Med Hypotheses. 2020 Nov; 144:110031. Kumar Raghav P, Mohanty S. PMID: 33254479; PMCID: PMC7313523.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    17. CancerEnD: A database of cancer associated enhancers. Genomics. 2020 09; 112(5):3696-3702. Kumar R, Lathwal A, Kumar V, Patiyal S, Raghav PK, Raghava GPS. PMID: 32360910.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    18. Docking-based approach for identification of mutations that disrupt binding between Bcl-2 and Bax proteins: Inducing apoptosis in cancer cells. Mol Genet Genomic Med. 2019 11; 7(11):e910. Raghav PK, Kumar R, Kumar V, Raghava GPS. PMID: 31490001; PMCID: PMC6825947.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    19. ccPDB 2.0: an updated version of datasets created and compiled from Protein Data Bank. Database (Oxford). 2019 01 01; 2019. Agrawal P, Patiyal S, Kumar R, Kumar V, Singh H, Raghav PK, Raghava GPS. PMID: 30689843; PMCID: PMC6343045.
      View in: PubMed   Mentions: 4     Fields:    
    20. Correction: Stem cell factor and NSC87877 combine to enhance c-Kit mediated proliferation of human megakaryoblastic cells. PLoS One. 2018; 13(12):e0210133. Raghav PK, Singh AK, Gangenahalli G. PMID: 30592765; PMCID: PMC6310269.
      View in: PubMed   Mentions:    Fields:    
    21. Stem cell factor and NSC87877 combine to enhance c-Kit mediated proliferation of human megakaryoblastic cells. PLoS One. 2018; 13(11):e0206364. Raghav PK, Singh AK, Gangenahalli G. PMID: 30388134; PMCID: PMC6214509.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    22. Stem cell factor and NSC87877 synergism enhances c-Kit mediated proliferation of human erythroid cells. Life Sci. 2018 Dec 01; 214:84-97. Raghav PK, Singh AK, Gangenahalli G. PMID: 30308182.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    23. A change in structural integrity of c-Kit mutant D816V causes constitutive signaling. Mutat Res. 2018 03; 808:28-38. Raghav PK, Singh AK, Gangenahalli G. PMID: 29482074.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    24. Overview of Free Software Developed for Designing Drugs Based on Protein-Small Molecules Interaction. Curr Top Med Chem. 2018; 18(13):1146-1167. Agrawal P, Raghav PK, Bhalla S, Sharma N, Raghava GPS. PMID: 30117394.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    25. Stem cell fate and insight dependent design of molecules and their evaluation for gain-of therapeutic applications through response modification. 2016. Pawan Kumar Raghav . .
    26. Enhanced heterodimerization of Bax by Bcl-2 mutants improves irradiated cell survival. Apoptosis. 2013 Feb; 18(2):212-25. Verma YK, Raghav PK, Raj HG, Tripathi RP, Gangenahalli GU. PMID: 23154865.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    27. Peptide screening to knockdown Bcl-2's anti-apoptotic activity: implications in cancer treatment. Int J Biol Macromol. 2012 Apr 01; 50(3):796-814. Raghav PK, Verma YK, Gangenahalli GU. PMID: 22155216.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    28. Molecular dynamics simulations of the Bcl-2 protein to predict the structure of its unordered flexible loop domain. J Mol Model. 2012 May; 18(5):1885-906. Raghav PK, Verma YK, Gangenahalli GU. PMID: 21866316.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    Pawan Kumar's Networks
    Concepts (92)
    Derived automatically from this person's publications.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.